Preclinical Accelerators of Precision Medicine Todd R. Golub, M.D.

Slides:



Advertisements
Similar presentations
Regulation of Consumer Tests in California AAAS Meeting June 1-2, 2009 Beatrice OKeefe Acting Chief, Laboratory Field Services California Department of.
Advertisements

Ulrik Lassen MD, PH.D Phase 1 Unit
Zeroing in on Non-Small Cell Lung Cancer: Integrating Targeted Therapies into Practice.
CTD2 CTD2: Functional Cancer Genomics cancer genomics
Clinical Implementation of Genomic Cancer Medicine
Reported by R5 李霖昆 Supervised by 楊慕華 大夫 Genomics-Driven Oncology: Framework for an Emerging Paradigm Review article Journal of Clinical Oncology 31, 15,
The Pursuit of Better Medicines through Genetic Research Terri Arledge, DVM US Department Head Drug Development Genetics.
Evaluating cell lines as tumor models by comparison of genomic profiles Domcke, S. et al. Nat. Commun 4:2126.
Re-Examination of the Design of Early Clinical Trials for Molecularly Targeted Drugs Richard Simon, D.Sc. National Cancer Institute linus.nci.nih.gov/brb.
Curing Cancer 2015 update Jesse S. Boehm, Ph.D. Associate Director, Broad Institute Cancer Program.
Vs. home.ccr.cancer.gov Personalized medicine-The goal.
NIH Council of Councils Meeting November 21, 2008 LINCS Library of Integrated Network-based Cellular Signatures.
HIGH-THROUGHPUT MUTATION PROFILING OF OSTEOSARCOMA PRIMARY TUMORS AND CELL LINES IDENTIFIES NEW MUTATIONS IN PREVIOUSLY UNASSOCIATED ONCOGENES AND TUMOR.
Initiating phase 1 clinical trials in pediatric oncology National Cancer Institute Perspective Barry Anderson, MD, PhD Pediatric Section Cancer Therapy.
The Human Genome Project Eric Lander PhD Director Whitehead Center for Genome Research Cambridge, MA Eric Topol MD Provost and Chief Academic Officer Chairman.
The highlight of resistance mechanism of targeted therapy on clinical therapy Zuhua Chen Dep. of GI oncology.
NIH: A Time of Unprecedented Opportunity Senate Appropriations Subcommittee on Labor/HHS/Education Elias A. Zerhouni, M.D. Director.
NCI Initiatives to Develop Non-Clinical Models for Pediatric Oncology Malcolm A. Smith, MD, PhD 17 March 2004.
INTERPRETING GENETIC MUTATIONAL DATA FOR CLINICAL ONCOLOGY Ben Ho Park, M.D., Ph.D. Associate Professor of Oncology Johns Hopkins University May 2014.
Multi-scale network biology model & the model library 多尺度网络生物学模型 -- 兼论模型库的建立与应用 Jianghui Xiong 熊江辉
Moiz Bakhiet, MD, PhD, Professor and Chairman
Emerging Genomic Technologies: Extending the Application of Genomics to Prediction, Diagnosis, Monitoring, and Early Detection Luis A. Diaz, M.D. Johns.
Illustration of how the diagnostic yield changes as the size of the gene panel (number of genes) increases. The general characteristics of panels of various.
Big Data in Genomics, Diagnostics, and Precision Medicine
Samsung Genome Institute Samsung Medical Center
Natural History, Response to Treatment
NISCHR Academic Health Science Collaboration Launch
AACR Genomics In Clinical Medicine Think Tank
Figure 1. Resistance mechanism against first generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). (A) Mutations in the EGFR.
SI-II A SI-II. Expression analysis of bladder cancer functionally active genes and significantly mutated genes. Comprehensive transcriptome profiling of.
FREQUENCIES of altered genes RECURRENT variants & mutated genes
Accelerating Precision Medicine for Advanced Cancer Patients
Presented By John Bartlett at 2017 ASCO Annual Meeting
Multiple Myeloma Research Foundation
A Functional Map of Oncogenic States for Breast Cancer
OMICS Journals are welcoming Submissions
Crystal digital PCR for detection and quantification of circulating EGFR mutations in advanced non-small cell lung cancer Cécile Jovelet Postdocoral fellow.
Prediction of Optimal Cancer Drug therapies via SVM
Content and Labeling of Tests Marketed as Clinical “Whole-Exome Sequencing” Perspectives from a cancer genetics clinician and clinical lab director Allen.
The Genomics of Cancer and Molecular Testing:
Jeopardy Genes and Chromosomes
New Targets, New Modalities, New Challenges – The Inconvenient Path of Human Genetics in Drug Discovery Enabling Precision Medicine: The Role of Genetics.
Carlos L. Arteaga, Jeffrey A. Engelman  Cancer Cell 
Applying Genomic Profiling to Precision Cancer Medicine in Clinical Practice George D. Demetri MD Senior Vice-President for Experimental Therapeutics.
Accelerating drug discovery: Open source cancer cell biology?
By Michael Fraczek and Caden Boyer
Volume 9, Issue 6, Pages (June 2006)
Molecular Analysis of Circulating Cell-Free DNA from Lung Cancer Patients in Routine Laboratory Practice  Stephan Bartels, Sascha Persing, Britta Hasemeier,
Jesper B. Andersen, Snorri S. Thorgeirsson  Gastroenterology 
Lecture 7: Biological Network Crosstalk Y. Z
Volume 9, Issue 6, Pages (June 2006)
The Role of IDH Inhibitors in Hematologic Malignancies
How will cancer be treated in the 21st century?
ASSIGNMENT 10 Use the UP and DOWN tags as provided and query the LINCS. These are the KRAS-DEP (UP) and KRAS-IND (DOWN) gene signatures from Singh et al.
Precision Medicine A New Era Hazem Assi American University of Beirut
Volume 58, Issue 4, Pages (May 2015)
Variant Triaging and ESMO Guidelines
Personalized Medicine: Patient-Predictive Panel Power
Quality Improvement and Molecular Profiling in Advanced Non-Small Cell Lung Cancer.
Molecular prognostication of liver cancer: End of the beginning
Group 3 Group 3 The “Omes” Precision Cancer Medicine
role of comparative oncology in translational research
Rapid Polymerase Chain Reaction-Based Detection of Epidermal Growth Factor Receptor Gene Mutations in Lung Adenocarcinomas  Qiulu Pan, William Pao, Marc.
LLC cells exhibit a blunted response to IFNγ in vitro and in vivo compared with CMT167. LLC cells exhibit a blunted response to IFNγ in vitro and in vivo.
To Infinium, and Beyond! Cancer Cell
Targetable alterations and pathways in TNBCs after NAC
One potential implementation for the use of outlier kinase profiling and targeting for clinical management of pancreatic cancer in a precision medicine.
Global analysis of the chemical–genetic interaction map.
An isogenic cell line screen reveals genomic drivers of drug response.
Molecular characterization of esophagogastric tumors.
Presentation transcript:

Preclinical Accelerators of Precision Medicine Todd R. Golub, M.D. Broad Institute

Perspective on the human genome in 7 words

Genome: Bought the book, hard to read. -- Eric Lander, 2003 Perspective on the human genome in 7 words Genome: Bought the book, hard to read. -- Eric Lander, 2003

How will we learn how to interpret the cancer genome?

How will we learn how to interpret the cancer genome? By making genotype-clinical response associations

How will we learn how to interpret the cancer genome? By making genotype-clinical response associations By using systematic experimental models (even if imperfect) to guide clinical investigation

Interpreting variant alleles It’s now possible to synthesize all possible alleles of any cancer gene (e.g. EGFR)

gene expression profiling Interpreting variant alleles It’s now possible to synthesize all possible alleles of any cancer gene (e.g. EGFR) 96h gene expression profiling library of ORF alleles A549 lung cells

Gene expression signatures reflect allele activity

Gene expression signatures reflect allele activity Systematic assessment of all alleles for transforming and drug sensitivity also now feasible

WNT pathway Even known mutations often have no drugs targeting them J. Rosenbluh, M. Giannakis

WNT pathway Even known mutations often have no drugs targeting them Need to catalyze early drug discovery efforts against “undruggable” targets (e.g. NCI RAS initiative)

WNT pathway Even known mutations often have no drugs targeting them Need to catalyze early drug discovery efforts against “undruggable” targets (e.g. NCI RAS initiative) Need to systematically discover vulnerabilities associated with particular genotypes (Cancer Dependency Map)

Toward a comprehensive cancer dependency map

Recommendations Generate high quality functional look up tables for all alleles of known cancer genes Generate a comprehensive Cancer Dependency Map that relates molecular features of tumor cells to their vulnerabilities Use this experimental information to inform priority of clinical trials and interpretation of clinical data